Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression
- 1 June 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 13 (3) , 253-258
- https://doi.org/10.1097/00008390-200306000-00005
Abstract
Spontaneous regression of primary melanoma lesions is regarded as the result of the recognition of melanoma-associated antigen (MAA)-derived peptides by cytotoxic T-lymphocytes and destruction of melanoma cells. The transporter associated with antigen processing (TAP1/2) is likely to play a crucial role in this process since it loads antigen peptides onto MHC class I molecules. To determine the impact of TAP defects on the spontaneous regression of melanoma lesions, we have compared the expression of TAP1 and TAP2 in 39 primary melanoma lesions exhibiting clinical and histological signs of tumour regression and in 35 primary melanoma lesions without regression phenomena. TAP1 expression was significantly associated with regression of melanoma lesions, since the staining pattern with anti-TAP1 antibody was positive in 38 of the 39 lesions exhibiting regression phenomena and in only 24 of the 35 lesions without histopathological signs of tumour regression. In the latter group, six lesions were stained with a heterogeneous pattern and five with a negative pattern. Furthermore, in lesions with a heterogeneous staining pattern, a clear association was found between TAP1 expression in melanoma cells and the presence of tumour-infiltrating lymphocytes. These results suggest that TAP1 plays an important role in the MAA-specific cytotoxic T-lymphocyte response, which has been suggested to underlie the spontaneous regression of primary melanoma.Keywords
This publication has 23 references indexed in Scilit:
- Down-Regulation of HLA Class I Antigen-Processing Molecules in Malignant MelanomaThe American Journal of Pathology, 1999
- Transfection of TAP 1 gene restores HLA class I expression in human small-cell lung carcinomaInternational Journal of Cancer, 1998
- Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell linesInternational Journal of Cancer, 1997
- Peptide presentation by MHC class I moleculesTrends in Cell Biology, 1996
- Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell linesImmunology Letters, 1996
- Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing.The Journal of Experimental Medicine, 1994
- Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.The Journal of Experimental Medicine, 1994
- TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4−8+ T cellsCell, 1992
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984